Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology

Drug Profile

Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: DC activated CTL - Shenzhen Hornetcorn Biotechnology; DC-CTL - Shenzhen Hornetcorn Biotechnology; Dendritic cell cytotoxic T lymphocyte cell therapy - Shenzhen Hornetcorn Biotechnology

Latest Information Update: 20 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shenzhen Hornetcorn Biotechnology
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 06 May 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02766348)
  • 05 May 2016 Clinical trials in Non-small cell lung cancer in China (IV) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top